Cell Biology Program
The Xuejun Jiang Lab
The research of my laboratory focuses on two directions highly relevant to cancer biology, (1) the molecular basis of programmed cell death processes (including apoptosis and ferroptosis), and their roles in human disease; and (2) the molecular basis of autophagy and its role in cancer. We also study various cancer signaling and cellular metabolic events, especially those involved in cell death/survival determination. We aim to translate our basic research finding into potential therapeutic approaches. To achieve these goals, the laboratory utilizes a combination of approaches including biochemistry, chemical biology, proteomics, molecular cell biology, high-throughput screening, 3-dimensional microfluidic cell array, and mouse modeling.
Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, Cai Y, Gu W, Stockwell B, Jiang X. Ferroptosis surveillance independent of GPX and differentially regulated by sex hormones. Cell 2023 Jun22 (13) 2748-2764. [PMID: 37267948]
Zhang Z, Karthaus WR, Lee RS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Darnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X*, Watson PA*, Sawyers CL*. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell 2020 (38) 279-296. PMCID: PMC7472556 (*: co-corresponding authors)
Wu J, Minikes AM, Gao M, Bian H, Li Y, Stockwell BR, Chen ZN, Jiang X. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 2019 Aug:572(7770):E20, PMCID: PMC6697195
Xuejun Jiang, PhD
- Cell biologist Xuejun Jiang studies programmed cell death, molecular mechanisms, and their roles in tumorigenesis.
- PhD, University of Texas Southwestern Medical Center at Dallas
- Louis and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
- Scholar, American Cancer Society (2007-2010)
- Catherine and Frederick Adler Chair for junior faculty, Memorial Sloan Kettering Cancer Center (2006)
- V Scholar, The V Foundation for Cancer Research (2004-2006 )
- Alfred Bressler Scholar, Alref W. Bresller Scholars Fund (2004-2007)
- Sigma Xi Award, UT Southwestern (1998)
- Robert A. Welch Predoctoral Fellowship, UT Southwestern (1995-1999)
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Xuejun Jiang discloses the following relationships and financial interests:
Equity; Fiduciary Role / Position; Intellectual Property Rights; Professional Services and Activities
Lime Therapeutics, Inc.
Equity; Professional Services and Activities (Uncompensated)
VivoZ Biolabs, LLC
Intellectual Property Rights; Professional Services and Activities (Uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.